other_material
confidence high
sentiment positive
materiality 0.65
Contineum reports positive Phase 1b PET data for PIPE-791; confirms target engagement
Contineum Therapeutics, Inc.
- PIPE-791 achieved high LPA1 brain receptor occupancy in healthy volunteers and PrMS patients.
- Plasma EC50 of 37 ng/mL at 24h and 12 ng/mL at 168h shows sustained target engagement.
- Safety profile consistent with prior studies; no new safety signals identified.
- Planned Phase 2 doses expected to exceed 90% target coverage at trough with once-daily dosing.
- 12 healthy volunteers and 4 PrMS patients enrolled; trial met primary PK/RO correlation objectives.
item 7.01item 8.01item 9.01